BriaCell Therapeutics Corp.

Call Directions Website Contact the business

BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is developing therapies to destroy cancer

Join us in recognizing Men's Week, October 17-23. While breast cancer is more common in women, it can also affect men....
10/19/2026

Join us in recognizing Men's Week, October 17-23.

While breast cancer is more common in women, it can also affect men. This week, we're highlighting the importance of awareness, education and research for everyone impacted by breast cancer. Learn more: https://bit.ly/3EwJcKQ

BriaCell CEO Dr. William V. Williams joins Johny Fernandez of Fintech TV to discuss the company’s pivotal Phase 3 trial ...
10/19/2026

BriaCell CEO Dr. William V. Williams joins Johny Fernandez of Fintech TV to discuss the company’s pivotal Phase 3 trial of Bria-IMT and the progress toward its headline data readout.

Dr. Williams also highlights Bria-OTS, BriaCell’s off-the-shelf immunotherapy approach designed to match more than 99% of patients, and encouraging clinical results observed in metastatic breast cancer.

Watch the full interview: https://bit.ly/3CgzknU

On , we're highlighting the importance of screening and early detection.Regular screening can help detect breast canc...
10/16/2026

On , we're highlighting the importance of screening and early detection.

Regular screening can help detect breast cancer earlier, when it may be easier to treat. BriaCell is committed to advancing innovative approaches for people living with breast cancer.

Learn more: https://bit.ly/3DgtmSu

BriaCell President and CEO Dr. William V. Williams was featured as a key speaker at The Scientist’s Virtual Symposium, “...
10/15/2026

BriaCell President and CEO Dr. William V. Williams was featured as a key speaker at The Scientist’s Virtual Symposium, “The Translational Potential of Cell and Gene Therapies.”

The symposium brings together researchers and industry experts to discuss the development, optimization and translation of cell and gene therapies toward clinical applications across a range of disease areas.

Watch the full presentation: https://bit.ly/3CgzknU

October 13 is nationally recognized as , helping raise awareness of and the need for continued research toward new tr...
10/13/2026

October 13 is nationally recognized as , helping raise awareness of and the need for continued research toward new treatment options.

Learn more about metastatic breast cancer and how you can get involved: https://bit.ly/3EwJcKQ

BriaCell has been shortlisted for the 2026 Citeline Biotech Awards in the category of Excellence in Oncology!The award r...
10/12/2026

BriaCell has been shortlisted for the 2026 Citeline Biotech Awards in the category of Excellence in Oncology!

The award recognizes biotech companies advancing cancer treatment through scientific innovation and a commitment to addressing the needs of patients with limited treatment options.

Winners will be announced at the awards ceremony on November 12, 2026, in Boston, MA. Learn more: https://bit.ly/3GBbcB1

This , we’re highlighting the continued advancement of novel approaches for patients facing .Bria-IMT™ is BriaCell’s o...
10/07/2026

This , we’re highlighting the continued advancement of novel approaches for patients facing .

Bria-IMT™ is BriaCell’s off-the-shelf, cell-based immunotherapy being evaluated in a pivotal Phase 3 clinical trial in combination with an immune checkpoint inhibitor.

Learn more: https://bit.ly/3q4udjN

10/06/2026

BriaCell (Nasdaq: BCTX, BCTXL) (TSX: BCT) and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer ( ) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

The presentations will feature BriaCell’s personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro’s research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants.

Presentation details can be found here: https://bit.ly/4hvkTRN

BriaCell CEO Dr. William V. Williams was featured in Investor’s Business Daily discussing the renewed momentum surroundi...
10/02/2026

BriaCell CEO Dr. William V. Williams was featured in Investor’s Business Daily discussing the renewed momentum surrounding therapeutic cancer vaccines following recent Phase 3 results from and .

Dr. Williams shared his perspective on the potential of the approach and the broader role of mRNA technology in .

“I think the cancer space is definitely where the mRNA technology can shine,” said Dr. Williams.

Read the full Investor’s Business Daily article, here: https://bit.ly/3CgzknU

October marks .According to the American Cancer Society, breast cancer deaths in 2026 are estimated to be 42,670 (42,14...
10/01/2026

October marks .

According to the American Cancer Society, breast cancer deaths in 2026 are estimated to be 42,670 (42,140 women, 530 men), making breast cancer the second leading cause of cancer death in women. Learn more about breast cancer and the importance of awareness, research and continued innovation: https://bit.ly/3EwJcKQ

Address

2929 Arch Street, 3rd Floor
Philadelphia, PA
19104

Telephone

+18884856340

Website

Alerts

Be the first to know and let us send you an email when BriaCell Therapeutics Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to BriaCell Therapeutics Corp.:

Shortcuts

Share

Category